Company: LGN
Filing Date: 2025-07-15
Form Type: DRS/A
Source: 0000950123-25-006399
Chunk: 309

Company: Legence Corp.
Filing Date: 2025-07-15
Form: DRS/A
Chunk 309
---
 536 |
| Forfeited                           |     |             |   (260 | ) |     | $               | 406 |
| Outstanding as of December 31, 2024 |     |             | 28,443 |   |     | $               | 323 |

The grant-date fair value was estimated using the hybrid method for the year ended December 31, 2024 and the OPM for the years ended December 31, 2023 and 2022 with the following weighted-average assumptions for the interests granted:

|                         |     | Year Ended December 31, 
                    2024 |     | 2023 |     |  2022 |
|:------------------------|:----|------------------------:|:----|-----:|:----|------:|
| Expected dividend yield |     |                     — % |     |  — % |     |   — % |
| Risk-free interest rate |     |                    4.4% |     | 4.2% |     |  4.0% |
| Expected volatility     |     |                     61% |     |  55% |     | 70.0% |
| Expected life (years)   |     |                     3.7 |     |  4.9 |     |   3.1 |

Since certain liquidity events (including Change of Control) have not occurred since the adoption of the Plan, no compensation expense is recorded for equity-classified Performance Interests and Exit Interests for the years ended December 31, 2024, 2023 or 2022. As of December 31, 2024, the unrecognized compensation expense related to Performance Interests and Exit Interests is approximately $5.0 million and $4.2 million, respectively. As a liquidity event (including Change of Control) is not considered probable until it occurs, the Company does not estimate the time period for the compensation expense to be recognized. Restricted Series C Common Interests In connection with an acquisition in 2023, Parent issued as compensation for future services Restricted Series C Common Intereststo certain of the acquiree’s former shareholders and employees who became Company employees in connection with the acquisition .These awards are liability-classified. F-52

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 Legence Holdings LLC and Subsidiaries Notes to Consolidated Financial Statements